ProCE Banner Activity

ExpressPoints
Evolving Strategies Using BTK Inhibitors in CLL: A Selective Approach to Improve Patient Outcomes

Slideset Download
Download this short summary slideset of key takeaway points from a live presentation on the evolving role of BTK inhibitors for patients with CLL including the latest reported evidence.

Released: June 23, 2021

Expiration: June 22, 2022

No longer available for credit.

Share

Faculty

George Follows

George Follows, BM, BCh, PhD

Visiting Professor of Haematology
Department of Haematology
Anglia Ruskin Medical School
Consultant Haematologist
Department of Haematology
Cambridge University Hospitals
Cambridge, United Kingdom

Paolo Ghia

Paolo Ghia, MD, PhD

Professor of Medical Oncology
Division of Experimental Oncology
Università Vita-Salute San Raffaele
Milan, Italy

Veronique Leblond

Veronique Leblond, MD

Professor, Hematology
Sorbonne University
Head, Department of Hematology
Pitié Salpêtrière Hospital
Paris, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

George Follows, BM, BCh, PhD

Visiting Professor of Haematology
Department of Haematology
Anglia Ruskin Medical School
Consultant Haematologist
Department of Haematology
Cambridge University Hospitals
Cambridge, United Kingdom

Paolo Ghia, MD, PhD

Professor of Medical Oncology
Division of Experimental Oncology
Università Vita-Salute San Raffaele
Milan, Italy

Veronique Leblond, MD

Professor, Hematology
Sorbonne University
Head, Department of Hematology
Pitié Salpêtrière Hospital
Paris, France